title: Sexual dimorphism in schizophrenia: is there a need for gender-based protocols?
abstract: Gender differences have been reported in various aspects of schizophrenia, including its epidemiology, clinical course and the response to antipsychotic medications. Over the past few years the authors have been investigating sex differences in brain function in individuals with schizophrenia and have found an intriguing disturbance of normal sexual dimorphism during emotional and cognitive processing. These results can be partly accounted for by altered levels of sex steroid hormones (i.e., estrogen and testosterone) in patients. A handful of clinical research groups have tried low doses of estrogen, testosterone or their precursors as adjunct therapies to the currently available antipsychotic medications in women and men with schizophrenia. The results have been promising, but further investigation is warranted. In the future, new more specific steroidal compounds will be developed and we will see more studies examining sex differences in the brain, behavior and mental health problems. This research will help to identify individuals who may benefit greatest from adjunct hormonal therapies and will further our understanding of the etiology of schizophrenia and other psychiatric disorders.
authors: Department of Psychiatry, Université de Montréal, Centre de recherche Fernand-Seguin, 7331 Hochelaga, Montreal (QC), H1N 3V2, Canada. adrianna.mendrek@umontreal.ca
authors: Adrianna
authors: A
authors: Mendrek
authors: Emmanuel
authors: E
authors: Stip
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects; D001921:Brain / Q000473:pathology / Q000503:physiopathology; D005260:Female; D012739:Gonadal Steroid Hormones / Q000502:physiology; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D012727:Sex Characteristics
chemical_list: D014150:Antipsychotic Agents; D012739:Gonadal Steroid Hormones